HumanZyme® Launches New Human Cell-Expressed LIF (Leukemia Inhibitory Factor) For Stem Cell Research and Regenerative Medicine Applications
HumanZyme Inc. announces the launch of recombinant human LIF (Leukemia Inhibitory Factor), a new addition to their HumanKine product line of authentic human recombinant proteins expressed in human cells for stem cell research and regenerative medicine applications.
Chicago, IL (PRWEB) August 17, 2016
HumanZyme Inc., a leading supplier of novel human proteins and growth factors expressed in human cells enabling stem cell research and regenerative therapy applications, today announced the launch of a new HumanKine® authentic recombinant human protein, LIF (Leukemia Inhibitory Factor). Human-cell expressed LIF has native human glycosylation, important since LIF is a highly glycosylated protein, also ensuring the best possible stability and activity in cell culture. The new LIF introduction expands the HumanKine product line of high-quality, native human proteins expressed in human cells available from HumanZyme.
“This new LIF HumanKine protein is an important addition to our product line

